UK-based laboratory services provider Source BioScience has completed the acquisition of Cambridge Clinical Laboratories (CCL), expanding its clinical diagnostics portfolio.
The acquisition aims to deliver a range of preclinical and clinical testing services, strengthening Source BioScience’s position in the healthcare diagnostics sector.
It aligns with the company’s existing capabilities in genomics and multiomics and expands its clinical offerings to include molecular diagnostics, digital pathology, and clinical trial support.
Source BioScience chairman and CEO Jay LeCoque said: “We’re extremely pleased to welcome Cambridge Clinical Laboratories into our team here at Source Bioscience.
“CCL has a longstanding reputation for its expertise in personalised clinical diagnostic services, and as such, represented the ideal opportunity to complete our service offerings.
“By investing in a new clinical lab facility and bringing in the talented team at CCL, we will open up significant new market opportunities in clinical diagnostics and be able to support our customers through all stages of their programs.”
Based in Cambridge, CCL offers personalised healthcare diagnostic services in areas of oncology, virology, men’s health, gastroenterology, and fertility.
The acquisition leverages CCL’s expertise and advanced facilities to provide simplified testing services for preclinical and clinical research.
Source BioScience will integrate CCL’s staff and assets into its facilities at Vision Park to enhance existing services and explore new capabilities.
Building on its Source LDPath and Source Genomics solutions, Source BioScience continues to offer laboratory services in genomics, multiomics, and healthcare diagnostics
Cambridge Clinical Laboratories former CEO and CSO Tony Cooke said: “Source BioScience is a well-established leader in the biopharmaceutical and broader life science service sector.
“We welcome the opportunity to join forces with Source, which will allow us to bring together the talent and expertise of both companies, ultimately adding more capacity for customers to access these cutting-edge research services, and bring new therapies to patients, faster.”
